In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.

The group is expanding its mRNA-4359 trial to include first-line melanoma.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

The companies clash over survival curve similarities – and differences.

Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.

In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.

The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.